Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis -- BT051, a gut-restricted drug which is designed to target neutrophil migration and subsequent activation, was shown to be safe and well tolerated. CONCORD, Mass. [...]